Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.

Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S.

Trends Immunol. 2018 Jul 9. pii: S1471-4906(18)30109-1. doi: 10.1016/j.it.2018.06.001. [Epub ahead of print] Review.

PMID:
30001871
2.

The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.

Ko EC, Raben D, Formenti SC.

Clin Cancer Res. 2018 Jun 26. pii: clincanres.3620.2018. doi: 10.1158/1078-0432.CCR-17-3620. [Epub ahead of print]

PMID:
29945993
3.

Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway.

Durante M, Formenti SC.

Front Oncol. 2018 May 29;8:192. doi: 10.3389/fonc.2018.00192. eCollection 2018. Review.

4.

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.

Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, Pilones KA, Sarfraz Y, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Jun 15. doi: 10.1158/2326-6066.CIR-17-0581. [Epub ahead of print]

PMID:
29907693
5.

Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab.

Formenti SC, Demaria S.

J Clin Oncol. 2018 Jun 5:JCO2018787622. doi: 10.1200/JCO.2018.78.7622. [Epub ahead of print] No abstract available.

PMID:
29870291
6.

Hypofractionated Whole-Breast Irradiation in Women Less Than 50 Years Old Treated on 4 Prospective Protocols.

Shaikh F, Chew J, Hochman T, Purswani J, Maisonet O, Peat E, Huppert N, Cooper BT, Tam M, Goldberg JD, Perez CA, Formenti SC, Gerber NK.

Int J Radiat Oncol Biol Phys. 2018 Apr 19. pii: S0360-3016(18)30691-6. doi: 10.1016/j.ijrobp.2018.04.034. [Epub ahead of print]

PMID:
29859789
7.

Radiotherapy and checkpoint inhibitors: a winning new combination?

Ko EC, Formenti SC.

Ther Adv Med Oncol. 2018 Apr 11;10:1758835918768240. doi: 10.1177/1758835918768240. eCollection 2018. Review.

8.

Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?

Vanpouille-Box C, Formenti SC.

Trends Immunol. 2018 Jun;39(6):435-437. doi: 10.1016/j.it.2018.03.002. Epub 2018 Mar 26.

PMID:
29598848
10.

PTEN at the interface of immune tolerance and tumor suppression.

Brandmaier A, Hou SQ, Demaria S, Formenti SC, Shen WH.

Front Biol (Beijing). 2017 Jun;12(3):163-174. doi: 10.1007/s11515-017-1443-5. Epub 2017 Mar 4.

11.
12.

Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations.

Jones RD, Chapman CH, Holliday EB, Lalani N, Wilson E, Bonner JA, Movsas B, Kalnicki S, Formenti SC, Thomas CR Jr, Hahn SM, Liu FF, Jagsi R; Society of Chairs of Academic Radiation Oncology Programs (SCAROP).

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):30-45. doi: 10.1016/j.ijrobp.2018.01.012. Epub 2018 Jan 9.

PMID:
29477292
13.

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.

Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH.

Clin Cancer Res. 2018 Jun 1;24(11):2493-2504. doi: 10.1158/1078-0432.CCR-17-3322. Epub 2018 Feb 23.

PMID:
29476019
14.

Using immunotherapy to boost the abscopal effect.

Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC.

Nat Rev Cancer. 2018 May;18(5):313-322. doi: 10.1038/nrc.2018.6. Epub 2018 Feb 16. Review.

15.

Optimizing Dose Per Fraction: A New Chapter in the Story of the Abscopal Effect?

Formenti SC.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):677-679. doi: 10.1016/j.ijrobp.2017.07.028. No abstract available.

PMID:
29280462
16.

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S.

Semin Cancer Biol. 2017 Dec 16. pii: S1044-579X(17)30252-3. doi: 10.1016/j.semcancer.2017.12.007. [Epub ahead of print] Review.

PMID:
29258856
17.

Integration of radiation and immunotherapy in breast cancer - Treatment implications.

Ye JC, Formenti SC.

Breast. 2018 Apr;38:66-74. doi: 10.1016/j.breast.2017.12.005. Epub 2018 Jan 4. Review.

PMID:
29253718
18.

Metastatic Osseous Pain Control: Radiation Therapy.

Kang J, Formenti SC.

Semin Intervent Radiol. 2017 Dec;34(4):322-327. doi: 10.1055/s-0037-1608703. Epub 2017 Dec 14. Review.

PMID:
29249855
19.

Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.

Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Feb;6(2):139-150. doi: 10.1158/2326-6066.CIR-17-0134. Epub 2017 Nov 27.

PMID:
29180535
20.

Trial watch: Immune checkpoint blockers for cancer therapy.

Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 Aug 31;6(11):e1373237. doi: 10.1080/2162402X.2017.1373237. eCollection 2017. Review.

PMID:
29147629
21.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

22.

TREX1 dictates the immune fate of irradiated cancer cells.

Vanpouille-Box C, Formenti SC, Demaria S.

Oncoimmunology. 2017 Jun 16;6(9):e1339857. doi: 10.1080/2162402X.2017.1339857. eCollection 2017.

23.

Emotional Intelligence and Burnout in Academic Radiation Oncology Chairs.

Holliday EB, Bonner JA, Formenti SC, Hahn SM, Kalnicki S, Liu FF, Movsas B, Fuller CD, Thomas CR Jr.

J Healthc Manag. 2017 Sep/Oct;62(5):302-313. doi: 10.1097/JHM-D-16-00001.

PMID:
28885530
24.

In Regard to Rahimi et al.

Gerber NK, Formenti SC.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):498-499. doi: 10.1016/j.ijrobp.2017.05.047. No abstract available.

PMID:
28872002
25.

Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.

Vanpouille-Box C, Formenti SC, Demaria S.

Clin Cancer Res. 2018 Jan 15;24(2):259-265. doi: 10.1158/1078-0432.CCR-16-0037. Epub 2017 Jul 27. Review.

PMID:
28751442
26.

Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters.

Cooper BT, Li X, Shin SM, Modrek AS, Hsu HC, DeWyngaert JK, Jozsef G, Lymberis SC, Goldberg JD, Formenti SC.

Adv Radiat Oncol. 2016 Aug 9;1(4):373-381. doi: 10.1016/j.adro.2016.08.001. eCollection 2016 Oct-Dec.

27.

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S.

Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618.

28.

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P.

Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.

29.

Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer.

Formenti SC, Golden EB, Goldberg JD, Li X, Taff J, Fenton-Kerimian MB, Chandrasekhar S, Demaria S, Novik Y.

Oncoimmunology. 2016 Dec 27;6(3):e1274479. doi: 10.1080/2162402X.2016.1274479. eCollection 2017.

30.

Barriers to Radiation-Induced In Situ Tumor Vaccination.

Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, Rudqvist NP, Formenti SC, Demaria S.

Front Immunol. 2017 Mar 13;8:229. doi: 10.3389/fimmu.2017.00229. eCollection 2017. Review.

31.

Does Heavy Ion Therapy Work Through the Immune System?

Durante M, Brenner DJ, Formenti SC.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):934-936. doi: 10.1016/j.ijrobp.2016.08.037. Epub 2016 Sep 5. No abstract available.

PMID:
27869095
32.

Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.

Galluzzi L, Bravo-San Pedro JM, Demaria S, Formenti SC, Kroemer G.

Nat Rev Clin Oncol. 2017 Apr;14(4):247-258. doi: 10.1038/nrclinonc.2016.183. Epub 2016 Nov 15. Review.

PMID:
27845767
33.

Radiotherapy: Changing the Game in Immunotherapy.

Demaria S, Coleman CN, Formenti SC.

Trends Cancer. 2016 Jun;2(6):286-294. Review.

34.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

35.

Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure.

Katz A, Formenti SC, Kang J.

Front Oncol. 2016 Jul 8;6:168. doi: 10.3389/fonc.2016.00168. eCollection 2016.

36.

The Pace of Progress in Radiation and Immunotherapy.

Formenti SC.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1257-8. doi: 10.1016/j.ijrobp.2016.02.063. No abstract available.

PMID:
27354133
37.

Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?

Demaria S, Formenti SC.

J Immunother Cancer. 2016 May 17;4:29. doi: 10.1186/s40425-016-0133-1. eCollection 2016.

38.

Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed.

Cooper BT, Formenti-Ujlaki GF, Li X, Shin SM, Fenton-Kerimian M, Guth A, Roses DF, Hitchen CJ, Rosenstein BS, Dewyngaert JK, Goldberg JD, Formenti SC.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):571-8. doi: 10.1016/j.ijrobp.2015.12.373. Epub 2015 Dec 29.

PMID:
27131077
39.

Silvia Formenti on the promise of combining radiotherapy and immunotherapy to treat cancer.

Formenti SC.

Oncology (Williston Park). 2016 Apr;30(4):289, 292. No abstract available.

40.

Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled Clinical Trial Evaluating Different Tumor Bed Boost Fractionations.

Finkel MA, Cooper BT, Li X, Fenton-Kerimian M, Goldberg JD, Formenti SC.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):579-89. doi: 10.1016/j.ijrobp.2016.02.004. Epub 2016 Feb 6.

PMID:
27045811
41.

Subverting misconceptions about radiation therapy.

Formenti SC, Demaria S, Barcellos-Hoff MH, McBride WH.

Nat Immunol. 2016 Apr;17(4):345. doi: 10.1038/ni.3363. No abstract available.

PMID:
27002831
42.

Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes.

Pham A, Arora S, Wernicke AG, Kutler DI, Cohen M, Kuhel W, Trichter S, Nori D, Formenti SC, Parashar B.

J Contemp Brachytherapy. 2015 Dec;7(6):445-52. doi: 10.5114/jcb.2015.56764. Epub 2015 Dec 30.

43.

Breast, chest wall, and nodal irradiation with prone set-up: Results of a hypofractionated trial with a median follow-up of 35 months.

Shin SM, No HS, Vega RM, Fenton-Kerimian M, Maisonet O, Hitchen C, Keith DeWyngaert J, Formenti SC.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):e81-8. doi: 10.1016/j.prro.2015.10.022. Epub 2015 Nov 9.

PMID:
26723552
44.

Pro-oncogenic cytokines and growth factors are differentially expressed in the post-surgical wound fluid from malignant compared to benign breast lesions.

Valeta-Magara A, Hatami R, Axelrod D, Roses DF, Guth A, Formenti SC, Schneider RJ.

Springerplus. 2015 Sep 5;4:483. doi: 10.1186/s40064-015-1260-8. eCollection 2015.

45.

Role of Local Radiation Therapy in Cancer Immunotherapy.

Demaria S, Golden EB, Formenti SC.

JAMA Oncol. 2015 Dec;1(9):1325-32. doi: 10.1001/jamaoncol.2015.2756. Review.

PMID:
26270858
46.

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S.

Vaccine. 2015 Dec 16;33(51):7415-7422. doi: 10.1016/j.vaccine.2015.05.105. Epub 2015 Jul 3. Review.

47.

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC.

Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18.

PMID:
26095785
48.

Society of Chairs of Academic Radiation Oncology Programs-Endorsed Radiation Oncology Department Review Process.

Thomas CR Jr, Bonner JA, Hahn SM, Lawrence TS, Liu FF, Formenti SC; Society of Chairs of Academic Radiation Oncology Programs.

Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):536-9. doi: 10.1016/j.ijrobp.2015.02.040. No abstract available.

PMID:
26068488
49.

Is classical stereotactic radiotherapy the optimal partner for immunotherapy?

Formenti SC.

Oncology (Williston Park). 2015 May;29(5):340, 347, 387. No abstract available.

50.

Raising the next generation of physician-scientists: the chairs' perspective.

Formenti SC, Bonner JF, Hahn SM, Lawrence TS, Liu FF, Thomas CR Jr.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):211-3. doi: 10.1016/j.ijrobp.2015.01.038. No abstract available.

PMID:
25968820

Supplemental Content

Loading ...
Support Center